The Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China-Reference-Cited by-同舟云学术

The Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China

Published:2023-08 Issue: Volume:Volume 16 Page:5055-5064
ISSN:1178-6973
Container-title:Infection and Drug Resistance
language:en
Short-container-title:IDR

Author:

Ke Hui,Gui Xuwei,Sun Wenwen,Zhang Shaojun,Yang Yan,Zhang Zhemin,Fan Lin^ORCID

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases,Pharmacology

Reference40 articles.

1. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization. 2014. Available from: www.who.int/about/licensing/copyright_form/en/index.html. Accessed July 27, 2023.

2. World Health Organization. Global tuberculosis report 2017. Licence: CC BY-NCSA 30 IGO. Geneva: World Health Organization; 2017.

3. World Health Organization. Global tuberculosis report 2022. License: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2022.

4. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications

5. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia—an observational cohort study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Outcomes and Associated Influencing Factors Among Patients with Rifampicin-Resistant Tuberculosis: A Multicenter, Retrospective, Cohort Study in China;Infection and Drug Resistance;2024-08

2. Bedaquiline;Reactions Weekly;2024-07-13